By Kira Lerner ( February 3, 2014, 6:26 PM EST) -- Belgian biopharmaceutical company Ablynx NV has inked a licensing agreement with Merck & Co. Inc. worth up to €1.7 billion ($2.3 billion) to develop methods for the body to fight cancer by activating the immune system, the companies said Monday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.